Developments in drugs for ovarian stimulation (Q35131915)

6 August 2017

1 reference

title

Developments in drugs for ovarian stimulation (English)

1 reference

6 August 2017

C Yding Andersen

1 reference

6 August 2017

M Ludwig

1 reference

6 August 2017

L G Westergaard

series ordinal

1 reference

6 August 2017

K Diedrich

series ordinal

1 reference

6 August 2017

publication date

1 April 2003

1 reference

Best Practice & Research: Clinical Obstetrics & Gynaecology

6 August 2017

published in

1 reference

6 August 2017

1 reference

6 August 2017

1 reference

6 August 2017

page(s)

231-247

1 reference

Human chorionic gonadotropin in commercial human menopausal gonadotropin preparations

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2802%2900168-2

7 January 2021

Composition of commercial gonadotrophin preparations extracted from human post-menopausal urine: characterization of non-gonadotrophin proteins

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2802%2900168-2

7 January 2021

Purification and separation of follicle stimulating hormone (FSH) and luteinizing hormone (LH) from human menopausal gonadotrophin (HMG). 3. Effects of a biologically apparently pure FSH preparation on ovaries and uteri of intact, immature mice

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2802%2900168-2

7 January 2021

Comparative pharmacokinetics of two urinary human follicle stimulating hormone preparations in healthy female and male volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2802%2900168-2

7 January 2021

Clinical-pharmacological studies on human menopausal gonadotrophin

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2802%2900168-2

7 January 2021

Role of LH and FSH in ovarian function

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2802%2900168-2

7 January 2021

Suppression of LH during ovarian stimulation: effects differ in cycles stimulated with purified urinary FSH and recombinant FSH.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2802%2900168-2

7 January 2021

Increased risk of early pregnancy loss by profound suppression of luteinizing hormone during ovarian stimulation in normogonadotrophic women undergoing assisted reproduction

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2802%2900168-2

7 January 2021

Induction of multiple follicular growth in normally menstruating women with endogenous gonadotropin suppression

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2802%2900168-2

7 January 2021

The routine use of gonadotropin-releasing hormone agonists prior to in vitro fertilization and gamete intrafallopian transfer: a meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2802%2900168-2

7 January 2021

Reevaluation of the roles of luteinizing hormone and follicle-stimulating hormone in the ovulatory process

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2802%2900168-2

7 January 2021

Reduced in-vitro fertilization of human oocytes from patients with raised basal luteinizing hormone levels during the follicular phase

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2802%2900168-2

7 January 2021

Effect of high tonic levels of luteinising hormone on outcome of in-vitro fertilisation

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2802%2900168-2

7 January 2021

Hypersecretion of luteinising hormone, infertility, and miscarriage

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2802%2900168-2

7 January 2021

Randomized controlled trial of follicle stimulating hormone versus human menopausal gonadotrophin in in-vitro fertilization*

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2802%2900168-2

7 January 2021

Follicle-stimulating hormone or human menopausal gonadotropin for ovarian stimulation in in vitro fertilization cycles: a meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2802%2900168-2

7 January 2021

A prospective, randomized, assessor-blind, multicentre study comparing recombinant and urinary follicle stimulating hormone (Puregon versus Metrodin) in in-vitro fertilization

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2802%2900168-2

7 January 2021

Effects of profound suppression of luteinizing hormone during ovarian stimulation on follicular activity, oocyte and embryo function in cycles stimulated with purified follicle stimulating hormone

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2802%2900168-2

7 January 2021

Suppression of LH during ovarian stimulation: analysing threshold values and effects on ovarian response and the outcome of assisted reproduction in down-regulated women stimulated with recombinant FSH.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2802%2900168-2

7 January 2021

Human menopausal gonadotropin versus recombinant follicle-stimulating hormone in normogonadotropic women down-regulated with a gonadotropin-releasing hormone agonist who were undergoing in vitro fertilization and intracytoplasmic sperm injection: a

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2802%2900168-2

7 January 2021

HMG is as good as recombinant human FSH in terms of oocyte and embryo quality: a prospective randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2802%2900168-2

7 January 2021

A randomized prospective assessor-blind evaluation of luteinizing hormone dosage and in vitro fertilization outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2802%2900168-2

7 January 2021

Impact of recombinant follicle-stimulating hormone and human menopausal gonadotropins on in vitro fertilization outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2802%2900168-2

7 January 2021

Human recombinant luteinizing hormone is as effective as, but safer than, urinary human chorionic gonadotropin in inducing final follicular maturation and ovulation in in vitro fertilization procedures: results of a multicenter double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2802%2900168-2

7 January 2021

Recombinant human chorionic gonadotropin (rhCG) in assisted reproductive technology: results of a clinical trial comparing two doses of rhCG (Ovidrel) to urinary hCG (Profasi) for induction of final follicular maturation in in vitro fertilization-em

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2802%2900168-2

7 January 2021

A prospective, randomized, controlled, double-blind, double-dummy comparison of recombinant and urinary HCG for inducing oocyte maturation and follicular luteinization in ovarian stimulation

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2802%2900168-2

7 January 2021

Initiation of periovulatory events in gonadotrophin-stimulated macaques with varying doses of recombinant human chorionic gonadotrophin

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2802%2900168-2

7 January 2021

Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2802%2900168-2

7 January 2021

Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin).

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2802%2900168-2

7 January 2021

Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2802%2900168-2

7 January 2021

Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2802%2900168-2

7 January 2021

Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2802%2900168-2

7 January 2021

Ovarian stimulation for assisted reproduction with HMG and concomitant midcycle administration of the GnRH antagonist cetrorelix according to the multiple dose protocol: a prospective uncontrolled phase III study

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2802%2900168-2

7 January 2021

The single or dual administration of the gonadotropin-releasing hormone antagonist Cetrorelix in an in vitro fertilization-embryo transfer program.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2802%2900168-2

7 January 2021

The use of a GnRH antagonist (Cetrorelix) in a single dose protocol in IVF-embryo transfer: a dose finding study of 3 versus 2 mg

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2802%2900168-2

7 January 2021

Significant reduction of the incidence of ovarian hyperstimulation syndrome (OHSS) by using the LHRH antagonist Cetrorelix (Cetrotide) in controlled ovarian stimulation for assisted reproduction

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2802%2900168-2

7 January 2021

Use of GnRH antagonists in ovarian stimulation for assisted reproductive technologies compared to the long protocol. Meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2802%2900168-2

7 January 2021

Hormone profiles under ovarian stimulation with human menopausal gonadotropin (hMG) and concomitant administration of the gonadotropin releasing hormone (GnRH)-antagonist Cetrorelix at different dosages

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2802%2900168-2

7 January 2021

Circulating concentrations of placenta protein 14 during the natural menstrual cycle in women significantly reflect endometrial receptivity to implantation and pregnancy during successive assisted reproduction cycles

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2802%2900168-2

7 January 2021

10.1016/S1521-6934(02)00168-2

Identifiers

DOI

1 reference

6 August 2017

1 reference